EDSA · NASDAQ
Edesa Biotech (EDSA) Stock Price & Fundamentals
Edesa Biotech (EDSA) closed at $215.85 on Oct 9, 2026, down 1.18% from the previous close of $218.42.
Share price, past year
1Y +14.02%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $215.85 |
| Sep 30, 2026 | $219.83 |
| Aug 31, 2026 | $216.15 |
| Jul 31, 2026 | $214.67 |
| Jun 30, 2026 | $219.32 |
| May 29, 2026 | $212.76 |
| Apr 30, 2026 | $205.67 |
| Mar 31, 2026 | $220.28 |
| Feb 27, 2026 | $211.03 |
| Jan 30, 2026 | $203.17 |
| Dec 31, 2025 | $198.17 |
| Nov 28, 2025 | $199.68 |
| Oct 31, 2025 | $193.42 |
Key statistics
- Market cap
- $2.08B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$14.10M
- Shares outstanding
- 9.6M
- Dividend yield
- —
- 52-week range
- $185.56 – $223.21
Edesa Biotech's market cap is $2.08B, based on a share price of $215.85 and 9.6M shares outstanding as of Jun 30, 2026.
Financials
Edesa Biotech reported revenue of $0.00 for fiscal 2021, down 100.00% from fiscal 2020.
Edesa Biotech reported a net loss of $7.19M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2021ended Sep 30, 2021 | $0.00 | −100.0% | −$13.34M | — | −$1.10 | −$13.67M |
| FY2020ended Sep 30, 2020 | $328.80K | +55.2% | −$6.36M | −1,935.3% | −$0.74 | −$4.99M |
| FY2018ended Sep 30, 2018 | $211.85K | −7.2% | −$5.04M | −2,378.6% | −$1.76 | −$5.00M |
| FY2017ended Sep 30, 2017 | $228.29K | −82.1% | −$5.03M | −2,203.7% | −$3.44 | −$5.00M |
| FY2016ended Sep 30, 2016 | $1.27M | +67.6% | −$5.03M | −395.2% | −$0.57 | −$4.91M |
| FY2015ended Sep 30, 2015 | $758.69K | +103.9% | −$2.84M | −374.7% | −$0.36 | −$4.69M |
| FY2014ended Aug 31, 2014 | $372.13K | −31.8% | — | — | −$1.11 | — |
| FY2013ended Aug 31, 2013 | $545.47K | +90.7% | — | — | −$2.81 | — |
| FY2012ended Aug 31, 2012 | $286.05K | — | — | — | −$0.13 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2021ended Sep 30, 2021 | $0.00 | — | −$0.29 |
| Q3 FY2021ended Jun 30, 2021 | $0.00 | — | −$0.36 |
| Q2 FY2021ended Mar 31, 2021 | $0.00 | — | −$0.19 |
| Q1 FY2021ended Dec 31, 2020 | $0.00 | — | −$0.26 |
| Q4 FY2020ended Sep 30, 2020 | $500.00 | — | −$0.22 |
| Q3 FY2020ended Jun 30, 2020 | $109.99K | — | −$0.20 |
| Q2 FY2020ended Mar 31, 2020 | $110.52K | — | −$0.17 |
| Q1 FY2020ended Dec 31, 2019 | $107.80K | — | — |
Company profile
- Name
- Edesa Biotech, Inc.
- Ticker
- EDSA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- C/O Fasken Martineau Dumoulin Llp, 333 Bay Street, Suite 2400, Toronto, M5H 2T6
- Incorporated in
- A1
- Fiscal year ends
- September
- SEC CIK
- 0001540159
Recent SEC filings
- Aug 20, 2026
- Aug 13, 2026
- Aug 13, 2026
- Jun 11, 2026
- Jun 5, 2026
- May 29, 2026
- May 15, 2026
- May 14, 2026
Frequently asked questions
What is Edesa Biotech's stock price?
Edesa Biotech (EDSA) closed at $215.85 on Oct 9, 2026, down 1.18% from the previous close of $218.42.
What is Edesa Biotech's market cap?
Edesa Biotech's market cap is $2.08B, based on a share price of $215.85 and 9.6M shares outstanding as of Jun 30, 2026.
How much revenue does Edesa Biotech make?
Edesa Biotech reported revenue of $0.00 for fiscal 2021, down 100.00% from fiscal 2020.
Does Edesa Biotech pay a dividend?
Edesa Biotech's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Edesa Biotech, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures